MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Stopped The study did not meet primary endpoint at Week 52. The study also did not meet key secondary efficacy endpoints. Pegcetacoplan (APL-2) was well tolerated in the study, and the data were consistent with the established safety profile.

Conditions

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease

Interventions

• DRUG: Pegcetacoplan (APL-2)
• OTHER: Placebo

Sponsor

Apellis Pharmaceuticals, Inc.